The Notice of Allowance from the USPTO is a significant milestone for Enveric Biosciences, as it indicates that the EVM301 series of drug candidates has met the necessary criteria for patent protection. This development could potentially lead to increased investor confidence in the company and its pipeline, resulting in a positive short-term impact on the stock price.